Therapeutic efficacy of Chloroquine for the treatment of uncomplicated Plasmodium vivax infection in Shewa Robit, Northeast Ethiopia
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The development of drug resistance to chloroquine is posing a challenge in the prevention and control efforts of malaria globally. Chloroquine is the first-line treatment for uncomplicated P.vivax in Ethiopia. Regular monitoring of anti-malarial drugs is recommended to help early detection of drug-resistant strains of malaria parasites before widely distributed. The emergence of P.vivax resistance to chloroquine in the country endangers the efficacy of P.vivax treatment. This study aimed to assess the therapeutic efficacy of chloroquine among uncomplicated P.vivax infections at Shewa Robit Health Center, northeast Ethiopia. Methods: One-arm in vivo prospective chloroquine efficacy study was conducted from November 2020 to March 2021. Ninety participants aged between 16 months to 60 years confirmed with P.vivax mono-infection microscopically were selected and treated with a 25 mg/kg standard dose of chloroquine over three days. Thick and thin blood smears were prepared and examined. Clinical examination was performed over 28 follow-up days. Hemoglobin concentration level was measured on days 0, 14, and 28. Result: Of the 90 enrolled participants, 86 (96%) completed their 28 days follow-up period. The overall cure rate of the drug was 98.8% (95% CI: 95.3–100%). All asexual stages and gametocytes were cleared within 48 hours with rapid clearance of fever. Hemoglobin concentration had significantly recovered between days 0 and 14, 0 and 28, and 14 and 28 days (P = 0.032, P<0.001, and P = 0.005), respectively. Fast resolution of clinical signs and symptoms was also observed. Severe adverse events were not recorded. Conclusion: The present study revealed that chloroquine remains an efficacious and safe drug in the study setting for treating uncomplicated P.vivax in the study area. Large-scale continuous surveillance is needed to monitor the development of resistance in due time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies across Ethiopia have highlighted the variability in the response of P. vivax to CQ monotherapy, indicating the potential spread of resistance [21–23].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
White, N. J. (2017) · Malaria Journal · doi:10.1186/s12936-017-1731-1 · Cited by 230 · cited 1×
“vivax [26] and could be a rapid and complete absorption of CQ in the gastrointestinal tract following oral administration [27].”
Background
Research works printed but not linked: 33
- World Health Organization, 2015, World Malaria Report 2015, 280, 10.30875/1cee73f9-en · DOI · Paper page
- MA Oboh, 2020, Rising report of Plasmodium vivax in sub-Saharan Africa: Implications for malaria elimination agenda, Scientific African, 10
- T File, 2019, A retrospective analysis on the transmission of Plasmodium falciparum and Plasmodium vivax: the case of Adama City, East Shoa Zone, Oromia, Ethiopia, Malar J, 18, 1, 10.1186/s12936-019-2827-6 · DOI
- RN Price, 2014, Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis, Lancet Infect Dis, 14, 982, 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
- S Getachew, 2015, Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia, Malar J, 14, 1, 10.1186/s12936-015-1041-4 · DOI · Paper page
- K Rieckmann, 1989, Plasmodium vivax resistance to chloroquine?, The Lancet, 334, 1183, 10.1016/S0140-6736(89)91792-3 · DOI · Paper page
- H Teka, 2008, Chloroquine-resistant plasmodium vivax malaria in Debre Zeit, Ethiopia, Malar J, 7, 1, 10.1186/1475-2875-7-220 · DOI · Paper page
- T Abreha, 2017, Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial, PLoS Med
- M Assefa, 2015, Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Hossana Health Care Centre, southern Ethiopia, Malar J, 14, 1, 10.1186/s12936-015-0983-x · DOI · Paper page
- ZZ Kanche, 2016, Therapeutic Efficacy of Chloroquine in Plasmodium Vivax at Health Centers in Jimma Town, South-West Ethiopia
- TT Shiferawu, 2021, Five-year trend analysis of malaria prevalence in Shewarobit, Amhara Regional State, North-central Ethiopia, Pan Afr Med J, 40, 237
- T Ketema, 2011, Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia, Parasit Vectors, 4, 1, 10.1186/1756-3305-4-46 · DOI · Paper page
- GR Awab, 2017, Chloroquine–primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: an open randomized superiority trial, Am J Trop Med Hyg, 97, 1782, 10.4269/ajtmh.17-0290 · DOI · Paper page
- HB Beyene, 2016, Efficacy of chloroquine for the treatment of vivax malaria in Northwest Ethiopia, PLoS One, 11, e0161483, 10.1371/journal.pone.0161483 · DOI · Paper page
- T Shumbej, 2019, Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Guragae zone southern Central Ethiopia, BMC Infect Dis, 19, 1, 10.1186/s12879-019-4055-7 · DOI · Paper page
- Shafiqullah Shafaq, 2017, First-line anti-malarial drug (chloroquine) efficacy study for the treatment of plasmodium vivax, Int J Adv Res, 5, 1294, 10.21474/IJAR01/4539 · doi:10.21474/ijar01/4539
- S Seifu, 2017, Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Shawa Robit Health Care Centre, North-East Ethiopia, Acta Trop, 171, 44, 10.1016/j.actatropica.2017.02.027 · DOI
- AM Yohannes, 2011, Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia, Am J Trop Med Hyg, 84, 137, 10.4269/ajtmh.2011.09-0723 · doi:10.4269/ajtmh.2011.09-0723
- C Barnadas, 2008, Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes, Antimicrob Agents Chemother, 52, 4233, 10.1128/AAC.00578-08 · DOI
- T Ketema, 2009, Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia, Malar J, 8, 1, 10.1186/1475-2875-8-177 · DOI
- J Ducharme, 1996, Clinical pharmacokinetics and metabolism of chloroquine, Clin Pharmacokinet, 31, 257, 10.2165/00003088-199631040-00003 · DOI · Paper page
- AA Romanovsky, 2005, Fever and hypothermia in systemic inflammation: recent discoveries and revisions, Front Biosci, 10, 2193, 10.2741/1690 · DOI · Paper page
- S Yeshanew, 2021, Efficacy Study of Chloroquine to Plasmodium vivax Malaria in Darimu and Bure Districts, Southwest Ethiopia, Infect Drug Resist, 14, 795, 10.2147/IDR.S300692 · DOI · Paper page
- C-H Jang, 2006, Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes, Rheumatol, 45, 703, 10.1093/rheumatology/kei282 · DOI · Paper page
- AF Slater, 1993, Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum, Pharmacol Ther, 57, 203, 10.1016/0163-7258(93)90056-J · DOI · Paper page
- WE Collins, 2003, A retrospective examination of anemia during infection of humans with Plasmodium vivax, Am J Trop Med Hyg, 68, 410, 10.4269/ajtmh.2003.68.410 · DOI
- NM Anstey, 2009, The pathophysiology of vivax malaria, Trends Parasitol, 25, 220, 10.1016/j.pt.2009.02.003 · DOI · Paper page
- R Fendel, 2010, Hemolysis is associated with low reticulocyte production index and predicts blood transfusion in severe malarial anemia, PloS one, 5, e10038, 10.1371/journal.pone.0010038 · DOI
- S Tatala, 1998, Low dietary iron availability is a major cause of anemia: a nutrition survey in the Lindi District of Tanzania, Am J Clin Nutr, 68, 171, 10.1093/ajcn/68.1.171 · DOI · Paper page
- JF Friedman, 2005, Human schistosomiasis and anemia: the relationship and potential mechanisms, Trends Parasitol, 21, 386, 10.1016/j.pt.2005.06.006 · DOI · Paper page
- JG Shaw, 2011, Iron deficiency anemia: focus on infectious diseases in lesser developed countries, Anemia
- R Selvam, 1996, Hematological impairments in recurrent Plasmodium vivax infected patients, Jpn J Med Sci Biol, 49, 151, 10.7883/yoken1952.49.151 · doi:10.7883/yoken1952.49.151
- AC Martins, 2015, Side effects of chloroquine and primaquine and symptom reduction in malaria endemic area (Mâncio Lima, Acre, Brazil), Interdiscip Perspect Infect Dis
Cited by
Getu, E., Biruksew, A., Eshetu, T., Abamecha, A., Assefa, D. G., Mohammed, H., Wuletaw, Y., Tasew, G., Tollera, G., Hailu, M., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05446-y · Cited by 4
Self-citation
Metadata
- Authors
- Belay, H., Alemu, M., Hailu, T., Mohammed, H., Sime, H., Hailegeorgies, H., Gidey, B., Haile, M., Assefa, G., Bekele, W., Alebachew Reta, M., Almaw Tamene, A., Tasew, G., & Assefa, A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2023-01-12
- Volume
- 18
- Issue
- 1
- Pages
- e0277362
- ISSN
- 1932-6203
- Cited by
- 11
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic efficacy of Chloroquine for the treatment of uncomplicated Plasmodium vivax infection in Shewa Robit, Northeast Ethiopia. https://app.cochat.ai/papers/10.1371/journal.pone.0277362
- The paper
- Belay, H., Alemu, M., Hailu, T., Mohammed, H., Sime, H., Hailegeorgies, H., Gidey, B., Haile, M., Assefa, G., Bekele, W., Alebachew Reta, M., Almaw Tamene, A., Tasew, G., & Assefa, A. (2023). Therapeutic efficacy of Chloroquine for the treatment of uncomplicated Plasmodium vivax infection in Shewa Robit, Northeast Ethiopia. PLOS ONE. https://doi.org/10.1371/journal.pone.0277362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.